Search company, investor...

Solace Therapeutics

solacetx.com

Stage

Loan | Alive

Total Raised

$31.68M

Last Raised

$250K | 3 yrs ago

About Solace Therapeutics

Solace Therapeutics is a medical device company focused on the development of non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). Solace is dedicated to improving the patient's quality of life by eliminating side effects typically associated with current drug and surgical therapies.

Headquarters Location

135 Newbury Street

Framingham, Massachusetts, 01701,

United States

508-283-1200

Missing: Solace Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Solace Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Solace Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Solace Therapeutics is included in 3 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

1,484 items

Startups focused on providing products and services catering to women's health and wellbeing.

M

Medical Devices

11,693 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Solace Therapeutics Patents

Solace Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • Fluid dynamics
  • Medical equipment
  • Digestive system surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/23/2020

12/14/2021

Fluid dynamics, Urology, Urinary system, Gynaecology, Incontinence

Grant

Application Date

4/23/2020

Grant Date

12/14/2021

Title

Related Topics

Fluid dynamics, Urology, Urinary system, Gynaecology, Incontinence

Status

Grant

Latest Solace Therapeutics News

Solace Therapeutics Announces that Dr. Cindy Basinski and Team at CMB Research Enrolls First Patient in US Pivotal Clinical Trial, using New Office-Based Treatment for Female Stress Urinary Incontinence (SUI)

Apr 21, 2021

Download April 21, 2021 09:00 AM Eastern Daylight Time NEWBURGH, Ind.--( BUSINESS WIRE )--Dr. Cindy Basinski and Team at CMB Research, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure. “I am delighted to be participating in the VESAIR Clinical Study. SUI is not life-threatening, but if left untreated, it can greatly diminish a woman’s Quality of Life. Having a non-surgical option would be a great alternative for the nearly 1 in 2 women over the age of 50, who suffer from this condition,” said Cindy Basinski, MD, Principal Investigator for the VESAIR Clinical Study. About Stress Urinary Incontinence and the Vesair Bladder Control System Women with Stress Urinary Incontinence (SUI) typically experience sudden increases in bladder pressure during physical movement, for example coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethral sphincter to withstand pressure, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure force, the Vesair Bladder Control System is designed to reduce rapid increases in bladder pressure through the placement of a compressible air-filled balloon in the bladder. The balloon acts like a “shock-absorber” to slow rapid changes in pressure and reduce leakage. The uninflated balloon is placed into the bladder through the urethra and subsequently inflated. Balloon placement is performed during an in-office procedure that does not require anesthesia. When necessary, the balloon is deflated and removed in a similar in-office procedure. Most women manage their SUI with absorbent pads and are reluctant to undergo surgery for a variety of reasons. To learn more about the VESAIR Clinical Trial visit; www.vesairstudy.com . About Solace Therapeutics, Inc. Solace Therapeutics is an emerging women’s health company focused on a new office-based treatment for symptoms of female SUI. SUI is the most prevalent form of incontinence among women and affects an estimated 15 million adult women in the U.S. These women choose to manage their SUI by utilizing absorbent products such as protective pads versus seeking medical help. Solace is dedicated to improving the quality of life for women whose daily life is disrupted by their incontinence. Please visit www.solacetx.com to learn more about the company and review results from the first two clinical trials. Contacts

Solace Therapeutics Frequently Asked Questions (FAQ)

  • Where is Solace Therapeutics's headquarters?

    Solace Therapeutics's headquarters is located at 135 Newbury Street, Framingham.

  • What is Solace Therapeutics's latest funding round?

    Solace Therapeutics's latest funding round is Loan.

  • How much did Solace Therapeutics raise?

    Solace Therapeutics raised a total of $31.68M.

  • Who are the investors of Solace Therapeutics?

    Investors of Solace Therapeutics include Paycheck Protection Program, Spray Venture Partners, New Enterprise Associates, Lightstone Ventures, Questa Capital and 3 more.

  • Who are Solace Therapeutics's competitors?

    Competitors of Solace Therapeutics include NeoChord, On-X Life Technologies, CreatiVasc Medical, Oraya Therapeutics, Syncro Medical Innovations and 12 more.

Compare Solace Therapeutics to Competitors

A
Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

S
Satiety

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

S
SonarMed

SonarMed is a medical device company founded on technology developed at Purdue University. The company's first product - the SonarMed AirWave - is a non invasive, adjunctive device that provides direct, precise, real time monitoring of endotracheal tube position and function, which may aid in detecting potentially dangerous or fatal endotracheal tube conditions. The AirWave may help reduce endotracheal tube related risks and complications, thereby improving patient safety and quality of care as well as reducing cost of care.

S
Spinal Restoration

Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.

U
Urovalve

Urovalve, Inc. has developed and patented technology to control fluid flow through small diameter flexible tubing. The core technology for the Surinate bladder management system is comprised of a magnetically controlled valve that can be activated remotely by a Surinate wearer who uses a hand held magnet to self-regulate flow. Currently available devices require continuous bladder drainage or insertion of a tube into the urethra several times each day. The Surinate bladder management system aims to provide a solution to the problems of life style, urinary tract infections, and substantial healthcare worker expenses associated with existing catheters.

N
Neurosonix

NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.